Paper41807883
BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.
Shang Y and 7 others. Mol Biomed, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations. Papers, record 41807883. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41807883
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Resistance, Neoplasm | Major topic |
| Melanoma | Major topic |
| Proto-Oncogene Proteins B-raf | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Humans | |
| Animals | |
| Tumor Microenvironment | |
| Mutation | |
| Antineoplastic Agents | |
| Epigenesis, Genetic | |
| Molecular Targeted Therapy |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82060503 | the National Natural Science Foundation of China Regional Project | PubMed | ||
| QKHJC -ZK [2022] General 622 | the Guizhou Province Science and Technology Plan Project | PubMed | ||
| QKHJC [2019] 1334 | the Guizhou Province Science and Technology Plan Project | PubMed | ||
| S202310661178 | National College Students Innovation and Entrepreneurship Training Program | PubMed | ||
| S202310661167 | National College Students Innovation and Entrepreneurship Training Program | PubMed | ||
| S2024106612300 | National College Students Innovation and Entrepreneurship Training Program | PubMed |
Source PubMed
References399
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38941889 | High levels of soluble CD73 unveil resistance to BRAF inhibitors in melanoma cells. | Biomed Pharmacother | 2024 | https://conductscience.org/library/papers/38941889 | PubMed |
| 2 | 40063190 | Let-7a microRNA modulates caspase-3-dependent apoptosis in melanoma cells treated with dabrafenib and trametinib combination. | Ir J Med Sci | 2025 | https://conductscience.org/library/papers/40063190 | PubMed |
| 3 | 33841154 | The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/33841154 | PubMed |
| 4 | 32626712 | Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma. | Front Cell Dev Biol | 2020 | https://conductscience.org/library/papers/32626712 | PubMed |
| 5 | 34831014 | IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34831014 | PubMed |
| 6 | 34304249 | Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. | Oncogene | 2021 | https://conductscience.org/library/papers/34304249 | PubMed |
| 7 | 33364196 | How Autophagy Shapes the Tumor Microenvironment in Ovarian Cancer. | Front Oncol | 2020 | https://conductscience.org/library/papers/33364196 | PubMed |
| 8 | 38946469 | Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study). | Neuro Oncol | 2024 | https://conductscience.org/library/papers/38946469 | PubMed |
| 9 | 29950559 | Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. | Nat Commun | 2018 | https://conductscience.org/library/papers/29950559 | PubMed |
| 10 | 39303722 | Integrated multi-omics analysis of zinc-finger proteins uncovers roles in RNA regulation. | Mol Cell | 2024 | https://conductscience.org/library/papers/39303722 | PubMed |
| 11 | 39175042 | Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib). | Cell Commun Signal | 2024 | https://conductscience.org/library/papers/39175042 | PubMed |
| 12 | 38008717 | Upregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin. | J Exp Clin Cancer Res | 2023 | https://conductscience.org/library/papers/38008717 | PubMed |
| 13 | 38593916 | Development and in-depth characterization of BRAFi-resistant melanoma cell lines in vitro and in vivo. | Exp Cell Res | 2024 | https://conductscience.org/library/papers/38593916 | PubMed |
| 14 | 40683333 | Deep Learning-Guided Quantitative Analysis Establishes Optimized BRAF V600E Immunohistochemical Criteria for Colorectal Cancer: A Multiplatform Validation Study. | Lab Invest | 2025 | https://conductscience.org/library/papers/40683333 | PubMed |
| 15 | 33827917 | Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/33827917 | PubMed |
| 16 | 36559089 | Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36559089 | PubMed |
| 17 | 34994998 | Curcumin suppresses cell proliferation and triggers apoptosis in vemurafenib-resistant melanoma cells by downregulating the EGFR signaling pathway. | Environ Toxicol | 2022 | https://conductscience.org/library/papers/34994998 | PubMed |
| 18 | 39297891 | Neddylation signaling inactivation by tetracaine hydrochloride suppresses cell proliferation and alleviates vemurafenib-resistance of melanoma. | Cell Biol Toxicol | 2024 | https://conductscience.org/library/papers/39297891 | PubMed |
| 19 | 32283823 | Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32283823 | PubMed |
| 20 | 38614086 | Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanoma. | Cell Rep | 2024 | https://conductscience.org/library/papers/38614086 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42898919 | miRNAs bridging the gap between the tumor microenvironment and liquid biopsy in cutaneous melanoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42898919 | PubMed |
| 42891779 | From MAPK Reactivation to Response: Clinical Approaches Targeting BRAF/MEK Resistance in Melanoma. | Am J Clin Dermatol | 2026 | https://conductscience.org/library/papers/42891779 | PubMed |
| 42797320 | Development of Degradable Silylated Castor Oil-Based Microparticles for the Sustained Release of a Lipophilic Anti-Cancer Drug. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42797320 | PubMed |
| 42729668 | TET2 downregulation limits oxidative stress-induced cytotoxicity of high dose ascorbate in dabrafenib-resistant melanoma cells. | Cancer Drug Resist | 2026 | https://conductscience.org/library/papers/42729668 | PubMed |
| 42553881 | Elucidating the Nexus of Mitochondrial Dysfunction and Oncometabolite Accumulation in Tumorigenesis. | Niger Med J | 2026 | https://conductscience.org/library/papers/42553881 | PubMed |
| 42429842 | Exploring the apoptotic potential of Prunus spinosa Trigno extract in BRAF-mutated melanoma cells. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42429842 | PubMed |
Genes202
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41807883
GET https://conductscience.org/api/papers/v1/41807883/references?page=2